Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
Summary
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and bra...
Description
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and bra...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source